Member info
Dr Marta Morales Ballús
Spain
Team
Dr Jaume Català Mora
Spain
Dr Elisa Carreras
Spain
Dr Itziar Alonso
Spain
Dr Isabel Ayet
Spain
Dr Ester Casas
Spain
Optometrist Ana Díaz
Spain
Dr Jesús Díaz
Spain
Optometrist Enric Puigventos
Spain
Optometrist Carles Fresno
Spain
Dr Carmen García Vicuña
Spain
Dr Hugo Gonzalez
Spain
Optometrist Enrique Jimenez
Spain
Dr Ana Llorca
Spain
Dr Antonio Federico Martinez Monstseny
Spain
Dr Joan Prat
Spain
Dr Gemma Romeu
Spain
Dr Alicia Serra
Spain
Optometrist Simone Suh
Spain
Dr Mariona Vidal
Spain
Optometrist Begoña Yeste
Spain
Dr Núria Planas
Spain
HCP Center
contact
Hospital Sant Joan de Déu, Spain
Clinical trials
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation